Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laura Arenare
Observed names:
Arenare, Laura,
L Arenare,
L. Arenare
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
University of Campania "Luigi Vanvitelli",
Ospedale Papa Giovanni XXIII,
Istituto Motori,
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
ORCID:
0000-0001-7100-4517
Observed ORCID:
0000-0001-7100-4517
OpenAlex ID:
A5023024840
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
2017
·
Jole Ventriglia
, Immacolata Paciolla
, et al.
·
Cancer Treatment Reviews
·
158
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
2020
·
Francesco Perrone
, Maria Carmela Piccirillo
, et al.
·
Journal of Translational Medicine
·
149
PDF
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
2019
·
Sabrina Chiara Cecere
, Gaia Giannone
, et al.
·
Gynecologic Oncology
·
112
PDF
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
2017
·
Sandro Pignata
, Giovanni Scambia
, et al.
·
Journal of Clinical Oncology
·
90
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
2019
·
Francesco Perrone
, Michelino De Laurentiis
, et al.
·
European Journal of Cancer
·
75
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
2022
·
Maria Carmela Piccirillo
, Laura Bonanno
, et al.
·
Journal of Thoracic Oncology
·
73
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system
2021
·
Silvia Riva
, Laura Arenare
, et al.
·
BMJ Open
·
54
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
2022
·
E.D. Capoluongo
, B. Pellegrino
, et al.
·
ESMO Open
·
48
PDF
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
2024
·
S. Pignata
, D. Califano
, et al.
·
Annals of Oncology
·
41
PDF
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin
2016
·
A. Bergamini
, C. Pisano
, et al.
·
Gynecologic Oncology
·
41
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial
2021
·
Antonio Avallone
, Maria C. Piccirillo
, et al.
·
JAMA Network Open
·
38
PDF
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
2021
·
Gennaro Daniele
, Francesco Raspagliesi
, et al.
·
International Journal of Gynecological Cancer
·
38
AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
2019
·
Francesca Collina
, Lucia La Sala
, et al.
·
Cancers
·
36
PDF
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
2021
·
Piera Gargiulo
, Laura Arenare
, et al.
·
BMC Cancer
·
31
PDF
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)
2022
·
Lucia Musacchio
, Daniela Califano
, et al.
·
British Journal of Cancer
·
29
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial
2024
·
Cristin Roma
, Riziero Esposito Abate
, et al.
·
European Journal of Cancer
·
26
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study
2021
·
Daniela Califano
, Daniela Gallo
, et al.
·
Cancers
·
25
PDF
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system
2020
·
Silvia Riva
, Fabio Efficace
, et al.
·
Supportive Care in Cancer
·
25
PDF
Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer
2015
·
Piera Gargiulo
, Laura Arenare
, et al.
·
Oncology
·
25
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials
2024
·
L. Arenare
, R. Di Liello
, et al.
·
ESMO Open
·
20
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
2018
·
J. Ventriglia
, I. Paciolla
, et al.
·
Clinical Oncology
·
20
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
2023
·
L. Arenare
, C. Porta
, et al.
·
ESMO Open
·
19
PDF
A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan
2020
·
Paolo Chiodini
, Laura Arenare
, et al.
·
Contemporary Clinical Trials Communications
·
17
PDF
The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid
2018
·
F. Perrone
, M. De Laurentiis
, et al.
·
Annals of Oncology
·
16
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial
2023
·
Lucia Musacchio
, Margherita Turinetto
, et al.
·
Gynecologic Oncology
·
15
Show more works
View as search
Works count:
120
Citation count:
1,645
H-index:
20
I10-index:
38
Year
Topic
Type